Cargando...
Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies
Cariprazine, a potent dopamine D(3) and D(2) receptor partial agonist antipsychotic with preferential binding to D(3) receptors, is Food and Drug Administration approved for treating schizophrenia and manic or mixed episodes of bipolar I disorder. A post-hoc safety/tolerability analysis of data from...
Gardado en:
| Publicado en: | Int Clin Psychopharmacol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Lippincott Williams And Wilkins
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5625952/ https://ncbi.nlm.nih.gov/pubmed/28692485 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/YIC.0000000000000187 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|